ReviewThe Yale journal of biology and medicine2011
Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.
Review in The Yale journal of biology and medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys.Journal of applied toxicology : JAT · 2016Trial
- ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy.Journal of translational medicine · 2025Article
- Integrating transcriptomic and metabolomic analyses to characterize the potential function of SLC1A5 in thyroid cancer.BMC cancer · 2025Article
- The emerging role of the branched chain aminotransferases, BCATc and BCATm, for anti-tumor T-cell immunity.Immunometabolism (Cobham, Surrey) · 2023Review
- Ferroptosis-related gene SLC1A5 is a novel prognostic biomarker and correlates with immune infiltrates in stomach adenocarcinoma.Cancer cell international · 2022Article
- Identification of critical amino acid residues in the regulatory N-terminal domain of PMEL.Scientific reports · 2021Article
- Article
- Cytotoxic T cells response with decreased CD4/CD8 ratio during mammary tumors inhibition in rats induced by non-contact electric fields.F1000Research · 2021Article
- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.Journal of immunology research · 2021Review
- Review
- Repeat domain-associated O-glycans govern PMEL fibrillar sheet architecture.Scientific reports · 2019Article
- XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.Frontiers in oncology · 2019Article
- Identifying the Most Effective Hydatid Cyst Fluid Fraction for Anticancer Vaccination of 4T1 Breast Tumor-Bearing Mice.International journal of preventive medicine · 2019Article
- Monoclonal antibodies in cancer immunotherapy.Molecular biology reports · 2018Review
- Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.Acta pharmacologica Sinica · 2018Review
- Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Article
- Melanosomal formation of PMEL core amyloid is driven by aromatic residues.Scientific reports · 2017Article
- Article
- Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer accounts for about every fourth death in the United States, with approximately 1,500 people dying each day as a result of this disease. Despite some progress in the last decades, these numbers alone undoubtedly demonstrate the urgent need for new and more efficient treatments. Immunotherapy aims to activate an efficient immune response against tumors or even prevent cancers from occurring in the first place. It is a growing field currently flourishing with several successful trials, some of which have led to the recent approval of new anti-cancer drugs by the Food and Drug Administration (FDA). This review addresses the manifold strategies that immunotherapy has taken in the past and discusses the most recent achievements in the field.
Indexed as
Identifiers
22180675PMC3238317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.